Michael J. Bannon

Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms.

The tachykinins comprise a family of closely related peptides that participate in the regulation of diverse biological processes. The tachykinin peptides substance P, neurokinin A, neurokinin A(3‐10), neuropeptide K, and neuropeptide γ are produced from a single preprotachykinin gene as a result of differential RNA splicing and differential posttranslational processing. Another tachykinin, neurokinin B, is produced from a separate preprotachykinin gene. These preprotachykinin mRNAs and peptide products are differentially distributed throughout the nervous system. Three distinct G protein‐coupled tachykinin receptors exist for these tachykinin peptides. The three receptors interact differentially with the tachykinin peptides and are uniquely distributed throughout the nervous system. The NK‐1 receptor preferentially interacts with substance P, the NK‐2 receptor prefers neurokinin A, neuropeptide K, and neuropeptide γ, and the NK‐3 receptor interacts best with neurokinin B. Examples of the roles of tachykinin peptidergic neuronal systems are taken from the spinal cord sensory system and the nigrostriatal extrapyramidal motor system. Analysis of the functional significance of multiple tachykinin peptide systems, receptor‐second messenger coupling mechanisms, and developmental and regulatory mechanisms underlying peptide mRNA and receptor expression represent areas of current and future investigation.—Helke, C. J.; Krause, J. E.; Mantyh, P. W.; Couture, R.; Bannon, M. J. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J. 4: 1606‐1615; 1990.

Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons

Electrophysiological and biochemical techniques were used to study midbrain dopamine systems. In the electrophysiological studies, projection areas of individual dopaminergic cells were identified by antidromic activation. Dopamine cells which innervate the piriform cortex and those that innervate the caudate nucleus demonstrated their usual dose-dependent inhibitory response to both the intravenous administration of the direct-acting dopamine agonist apomorphine and the microiontophoretic application of dopamine. In contrast, the firing rate of dopamine neurons which project to the prefrontal cortex and of those terminating in the cingulate cortex was not altered by either the intravenous administration of low to moderate doses of apomorphine or microiontophoretically applied dopamine. The mean basal discharge rate and degree of burst firing was also different between these subgroups of midbrain dopaminergic neurons. Mesoprefrontal and mesocingulate dopamine neurons had mean firing rates of 9.3 and 5.9 spikes/s respectively, and showed intense burst activity. Mesopiriform and nigrostriatal dopamine cells had discharge rates of 4.3 and 3.1 spikes/s and displayed only moderate bursting. The dopaminergic nature of those mesocortical neurons insensitive to apomorphine and dopamine was confirmed using combined intracellular recording and catecholamine histofluorescence techniques. Thus, after the intracellular injection of colchicine and subsequent processing for glyoxylic acid-induced histofluorescence, the injected cells could be identified by their brighter fluorescences compared to the surrounding, normally fluorescing, non-injected dopamine neurons. Using biochemical techniques, subgroups of midbrain dopaminergic systems were again found to differ. The administration of gamma-butyrolactone increased dopamine levels in all areas sampled (prefrontal, cingulate and piriform cortices as well as the caudate nucleus). However, although this effect was readily reversed in both the piriform cortex and caudate nucleus by pretreatment with apomorphine, this treatment had no effect on the increased dopamine levels observed in the prefrontal and cingulate cortices. In addition, the decline in dopamine levels after synthesis inhibition with alpha-methyltyrosine was significantly faster in the prefrontal and cingulate cortices relative to the caudate nucleus. The piriform cortex showed an intermediate decline which was not significantly different from that observed in any of the other regions.(ABSTRACT TRUNCATED AT 400 WORDS)

Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism

The importance of the nuclear receptor nurr1 for the appropriate development of mesencephalic dopamine‐synthesizing neurons has been clearly demonstrated through the targeted disruption of the nurr1 gene. The persistence of nurr1 expression in adult tissue suggests a possible role for this transcription factor in the maintenance, as well as development, of the dopaminergic phenotype. To address this issue, we analyzed the effects of nurr1 on the transcriptional expression of the human dopamine transporter gene (hDAT), one of the most specific phenotypic markers for dopaminergic neurons. Nurr1 enhanced the transcriptional activity of hDAT gene constructs transiently transfected into a newly described cell line (SN4741) that expresses a dopaminergic phenotype, whereas other members of the NGFI‐B subfamily of nuclear receptors had lesser or no effects. Nurr1 activation of hDAT was not dependent upon heterodimerization with the retinoid X receptor. Unexpectedly, functional analysis of a series of gene constructs revealed that a region of the hDAT 5′‐flanking sequence devoid of NGFI‐B response element (NBRE)‐like sites mediated nurr1 activation. Additional experiments using a nurr1 mutant construct suggest that nurr1 activates hDAT transcription via a novel NBRE‐independent mechanism.

The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons.

The dopamine (DAT) and serotonin (SERT) transporter genes both contain variable number of tandem repeats (VNTR) in non‐coding gene regions which have been correlated with a predisposition to a variety of CNS disorders. There is considerable homology between individual DAT and SERT repeat DNA sequences, which is reflected in their ability to compete with each other for specific protein binding as demonstrated by electrophoretic mobility shift assay. The SERT VNTR has recently been shown to act as a transcriptional enhancer. Because of the similarities between SERT and DAT VNTRs, the DAT VNTR may also enhance transcription. This study demonstrates by lipid transfection into an immortalized dopaminergic cell line and biolistic transfection into dopamine neurons in neonatal rat midbrain slices that the human nine‐repeat DAT VNTR can enhance transcription. This enhancing activity suggests that the DAT VNTR may play a role in regulation of DAT gene expression.

Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin

Chronic cocaine abuse induces long‐term neural adaptations as a consequence of alterations in gene expression. This study was undertaken to identify those transcripts differentially regulated in the nucleus accumbens of human cocaine abusers. Affymetrix microarrays were used to measure transcript abundance in 10 cocaine abusers and 10 control subjects matched for age, race, sex, and brain pH. As expected, gene expression of cocaine‐ and amphetamine‐regulated transcript (CART) was increased in the nucleus accumbens of cocaine abusers. The most robust and consistent finding, however, was a decrease in the expression of a number of myelin‐related genes, including myelin basic protein (MBP), proteolipid protein (PLP), and myelin‐associated oligodendrocyte basic protein (MOBP). The differential expression seen by microarray for CART as well as MBP, MOBP, and PLP was verified by RT–PCR. In addition, immunohistochemical experiments revealed a decrease in the number of MBP‐immunoreactive oligodendrocytes present in the nucleus accumbens and surrounding white matter of cocaine abusers. These findings suggest a dysregulation of myelin in human cocaine abusers.

The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders

The dopamine transporter is a plasma membrane protein that controls the spatial and temporal domains of dopamine neurotransmission through the accumulation of extracellular dopamine. The dopamine transporter may play a role in numerous dopamine-linked neuropsychiatric disorders. We review the cloning and organization of the human dopamine transporter gene, polymorphisms in its coding and noncoding sequence, and emerging data on its transcriptional regulation.

Acceleration by stress of dopamine synthesis and metabolism in prefrontal cortex: Antagonism by diazepam

SummaryUsing liquid chromatography and electrochemical detection (LCEC), we have measured the accumulation of 3,4-dihydroxyphenylalanine (DOPA) (after L-aromatic amino acid decarboxylase inhibition), dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in the frontal cortex and in the corpus striatum of the rat. Mild-footschock stress increased frontal cortex DOPA accumulation, as well as DA and DOPAC, without changing the concentration of these substances in the corpus striatum. The increases in cortical DA synthesis and metabolism were antagonized by diazepam which, given alone, tended to decrease DOPA accumulation to a small degree. In addition, we have measured the indoles serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), and the noradrenergic metabolite MHPG, none of which were altered by stress. The accumulation of 5-hydroxytryptophan (5-HTP) was also unaffected by stress but, like DOPA accumulation, was reduced to a small degree by diazepam.This study directly demonstrates a selective activation of frontal cortex catechol synthesis (in vivo tyrosine hydroxylation) by a mild stress, which did not significantly alter cortical noradrenergic or serotonergic metabolism.

Age‐related and regional differences in dopamine transporter mRNA expression in human midbrain

We assessed the abundance of dopamine transporter messenger RNA (DAT mRNA) in various human midbrain dopamine cell groups using in situ hybridization. The youngest individuals studied (17–23 years of age) exhibited significant regional heterogeneity of DAT expression, both in terms of the number of dopamine neurons expressing DAT mRNA and the abundance of DAT mRNA per cell, with the highest levels of expression evident within the ventral tier of the substantia nigra and lowest expression within the retrorubral field. In the older subjects (65–72 years old) analyzed, DAT mRNA in all regions was reduced to the level seen in the retrorubal field, indicating a positive correlation between initial levels of DAT expression and subsequent age-related reductions, with some regions exhibiting up to a 75% loss of DAT mRNA with age. The age-related decline in DAT mRNA was due to both a decrease in the abundance of DAT mRNA per dopamine cell as well as a decrease in the total number of dopamine cells expressing DAT mRNA, although tyrosine hydroxylase expression was less affected. These results indicate that changes in dopamine neurotransmission seen in normal aging may be related to altered DAT gene expression.

Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists

The effects of dopamine agonists and antagonists on rat basal ganglia substance P, substance K, and preprotachykinin mRNA were examined. Chronic administration of the prototypical dopamine antagonist haloperidol decreased striatal preprotachykinin mRNA and nigral tachykinin peptides. Chronic treatment with the dopamine D2 receptor antagonist L-sulpiride (but not the inactive D-isomer) mimicked the effect of haloperidol. In contrast, the atypical neuroleptic clozapine did not decrease tachykinin mRNA or peptides. The potent indirect dopamine agonist methamphetamine rapidly increased preprotachykinin mRNA, substance P, and substance K although the direct agonist apomorphine was without effect. Methamphetamine-stimulated changes in preprotachykinin mRNA were prevented by prior haloperidol administration. These data demonstrate that alterations in dopaminergic transmission significantly alter striatonigral tachykinin biosynthesis in vivo.

Regulators of G protein signaling: rapid changes in mRNA abundance in response to amphetamine.

Abstract: This study examined mRNAs encoding regulators of G protein signaling (RGSs) expressed within the striatum and determined whether their expression in the caudate putamen was altered by amphetamine. RT‐PCR techniques were used to clone cDNA probes of RGSs expressed within the rat striatum. Northern blot analysis of caudate putamen and nucleus accumbens RNA determined the relative abundance of RGS mRNA expressed within the caudate putamen and adjacent nucleus accumbens to be RGS 2 > RGS 5 > RGS 16 > RGS 4 = RGS 9 > RGS 8 = RGS 3. A single injection of amphetamine rapidly and transiently induced RGS 2 mRNA. The temporal pattern of induction of RGS 2 strongly resembled that of the immediate early gene c‐fos. Levels of mRNAs of RGS 3 and 5 steadily increased over a 4‐h interval, as did that of the 6.6‐kb transcript of RGS 8. The level of RGS 9 mRNA, which shows strong striatal‐specific expression, steadily decreased over a 4‐h interval, whereas RGS 4 and 16 and the 3.9‐kb transcript of RGS 8 were not significantly affected at any point examined. The ability of amphetamine to alter RGS mRNA expression within the caudate putamen suggests these proteins may play an important role in adaptive processes to psychostimulant exposure.